¼¼°èÀÇ ¾Ï·ÎµðÇÉ º£½Ç»ê¿° ½ÃÀå
Amlodipine Besylate
»óǰÄÚµå : 1533896
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 177 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,163,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,489,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¾Ï·ÎµðÇÉ º£½Ç»ê¿° ½ÃÀåÀº 2030³â±îÁö 13¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

2023³â¿¡ 12¾ï ´Þ·¯·Î ÃßÁ¤µÈ ¾Ï·ÎµðÇÉ º£½Ç»ê¿° ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 2.1%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç 2030³â¿¡´Â 13¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ °íÇ÷¾Ð ¾ÖÇø®ÄÉÀ̼ÇÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 2.3%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿©, ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§ 5¾ï 9,980¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½ÉÀ庴 ÀÀ¿ë ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 2.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3¾ï 1,460¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, Áß±¹Àº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 4.3%·Î ¼ºÀå ¿¹ÃøµË´Ï´Ù.

¹Ì±¹ÀÇ ¾Ï·ÎµðÇÉ º£½Ç»ê¿° ½ÃÀåÀº 2023³â 3¾ï 1,460¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°èÀÇ 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 2¾ï 6,130¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº 4.3%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº °¢°¢ 0.5%¿Í 1.5%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 1.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¾Ï·ÎµðÇÉ º£½Ç»ê¿° ½ÃÀå : ÁÖ¿ä ÃËÁø¿äÀΰú µ¿Çâ ¿ä¾à

¾Ï·ÎµðÇÉ º£½Ç»ê¿°Àº ÁÖ·Î °íÇ÷¾Ð(°íÇ÷¾ÐÁõ)°ú Çù½ÉÁõ(ÈäÅë)ÀÇ Ä¡·á¿¡ »ç¿ëµÇ´Â Ä®½· ä³Î Â÷´ÜÁ¦ÀÔ´Ï´Ù. ½É±Ù¼¼Æ÷³ª ÆòȰ±Ù¼¼Æ÷·ÎÀÇ Ä®½· ÀÌ¿ÂÀÇ À¯ÀÔÀ» ÀúÇØÇÔÀ¸·Î½á, ¾Ï·ÎµðÇÉ º£½Ç»ê¿°Àº Ç÷°üÀ» ÀÌ¿Ï,È®Àå½Ã۰í, Ç÷·ù¸¦ °³¼±Çϰí, ½ÉÀåÀÇ ÀÏ·®À» °¨¼Ò½Ãŵ´Ï´Ù. ÀÌ ÀÛ¿ë±âÀü¿¡ ÀÇÇØ ¾Ï·ÎµðÇÉ º£½Ç»ê¿°Àº ³úÁ¹Áß, ½ÉÀå ¹ßÀÛ, °íÇ÷¾Ð¿¡ ¼ö¹ÝÇÏ´Â ±âŸ ½ÉÇ÷°ü°è ÁúȯÀÇ ¿¹¹æ¿¡ È¿°úÀûÀÎ Ä¡·áÁ¦°¡ µË´Ï´Ù. ¾Ï·ÎµðÇÉ º£½Ç»ê¿°Àº 1ÀÏ 1ȸ °æ±¸ Á¤Á¦·Î ó¹æµÇ´Â °æ¿ì°¡ ¸¹À¸¸ç, ´Üµ¶ ¶Ç´Â ´Ù¸¥ ¹÷ ¾à¹°°ú ÇÔ²² »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

¼Ò°³ ÀÌÈÄ, ¾Ï·ÎµðÇÉ º£½Ç»ê¿°ÀÇ »ç¿ëÀº ÇöÀúÇÏ°Ô È®ÀåµÇ¾úÀ¸¸ç, ±× È¿°ú¿Í ¾ÈÀü¼ºÀº ¸¹Àº ¿¬±¸¿¡ ÀÇÇØ °ËÁõµÇ¾ú½À´Ï´Ù. ¾Ï·ÎµðÇÉ º£½Ç»ê¿°Àº ÇöÀç ¼¼°èÀûÀ¸·Î °¡Àå ÀϹÝÀûÀ¸·Î ó¹æµÇ´Â °íÇ÷¾Ð Ä¡·áÁ¦ Áß ÇϳªÀÔ´Ï´Ù. ¾Ï·ÎµðÇÉ º£½Ç»ê¿°ÀÇ ÀαâÀÇ ¿øÀÎÀº ´Ù¸¥ °íÇ÷¾Ð Ä¡·áÁ¦¿¡ ºñÇØ ºÎÀÛ¿ëÀÌ »ó´ëÀûÀ¸·Î °¡º±°í Àå±â »ç¿ë¿¡ ÀûÇÕÇÏ´Ù´Â °ÍÀÔ´Ï´Ù. ¶ÇÇÑ ¾Ï·ÎµðÇÉ º£½Ç»ê¿°Àº ´Üµ¶¿ä¹ýÀ¸·Îµµ ACE ¾ïÁ¦Á¦³ª ÀÌ´¢Á¦ µî ´Ù¸¥ ¾àÁ¦¿ÍÀÇ º´¿ë¿ä¹ýÀ¸·Îµµ ¹ü¿ë¼ºÀÌ Àֱ⠶§¹®¿¡ ÀÓ»ó ÇöÀå¿¡¼­ÀÇ À¯¿ë¼ºÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶Ç, ¾Ï·ÎµðÇÉ º£½Ç»ê¿°ÀÇ Á¦³×¸¯ ÀǾàǰÀÌ °³¹ßµÈ °ÍÀ¸·Î, ¾Ï·ÎµðÇÉ º£½Ç»ê¿°ÀÇ ÀÔ¼ö°¡ ¿ëÀÌÇØÁ®, °¡°Ýµµ Àú·ÅÇØÁø °Íµµ, ±× º¸±Þ¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. °íÇ÷¾Ð ¹× Çù½ÉÁõÀÇ Ä¡·á ¿Ü¿¡µµ ÇöÀç ÁøÇàÁßÀÎ ¿¬±¸´Â °ü»ó µ¿¸Æ Áúȯ ¹× ±âŸ ½ÉÇ÷°ü ÁúȯÀÇ °ü¸®¿¡¼­ ¿ªÇÒ°ú °°Àº ¾Ï·ÎµðÇÉ º£½Ç»ê¿°ÀÇ »õ·Î¿î ÀûÀÀ °¡´É¼ºÀ» ¸ð»öÇϰí ÀÖ½À´Ï´Ù.

¾Ï·ÎµðÇÉ º£½Ç»ê¿° ½ÃÀåÀÇ ¼ºÀåÀº ¿©·¯ ¿äÀο¡ ÀÇÇØ ¾ß±âµË´Ï´Ù. ù°, ¼¼°èÀÇ °íÇ÷¾Ð°ú ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϸé È¿°úÀûÀÎ Ç÷¾ÐÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µÑ°, °íÇ÷¾Ð°ú °ü·Ã Áúȯ¿¡ °É¸®±â ½¬¿î ¼¼°èÀÇ Àα¸ÀÇ °í·ÉÈ­´Â ¾Ï·ÎµðÇÉ º£½Ç»ê¿°°ú °°Àº Ä¡·áÁ¦ÀÇ Çʿ伺À» ´õ¿í ³ô¿©ÁÝ´Ï´Ù. ¶ÇÇÑ, Á¦¾à ¿¬±¸ÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀ¸·Î ȯÀÚÀÇ ÄÄÇöóÀÌ¾ð½º¿Í Ä¡·á ¼º°ú¸¦ Çâ»ó½ÃŰ´Â °³¼± µÈ Á¦Çü°ú º´¿ë ¿ä¹ýÀÌ °³¹ßµÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ½ÅÈï ½ÃÀå¿¡¼­ °Ç°­ °ü¸® ÀÎÇÁ¶ó¸¦ È®ÀåÇÏ¸é °íÇ÷¾Ð Ä¡·á¿¡ ´ëÇÑ ¾×¼¼½º¸¦ °³¼±ÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¦¾à±â¾÷ÀÇ Àü·«Àû ¸¶ÄÉÆÃ È°µ¿°ú ±³À°Àû ³ë·ÂÀ¸·Î °íÇ÷¾Ð °ü¸®¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁ® º¸´Ù ¸¹Àº ȯÀÚµéÀÌ Ä¡·á¸¦ ¹Þ°Ô µÇ°í ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ¾çÈ£ÇÑ ±ÔÁ¦È¯°æ°ú Á¦³×¸¯ ÀǾàǰ Áõ°¡·Î ¾Ï·ÎµðÇÉ º£½Ç»ê¿°Àº º¸´Ù ÀÔ¼ö°¡ ¿ëÀÌÇØÁö°í ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÁÖ¸ñÀÇ 36»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Amlodipine Besylate Market to Reach US$1.3 Billion by 2030

The global market for Amlodipine Besylate estimated at US$1.2 Billion in the year 2023, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 2.1% over the analysis period 2023-2030. High Blood Pressure Application, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$599.8 Million by the end of the analysis period. Growth in the Heart Disease Application segment is estimated at 2.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$314.6 Million While China is Forecast to Grow at 4.3% CAGR

The Amlodipine Besylate market in the U.S. is estimated at US$314.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$261.3 Million by the year 2030 trailing a CAGR of 4.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.5% and 1.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.0% CAGR.

Global Amlodipine Besylate Market - Key Drivers and Trends Summarized

Amlodipine is a calcium channel blocker medication primarily used to treat high blood pressure (hypertension) and angina (chest pain). By inhibiting the influx of calcium ions into cardiac and smooth muscle cells, amlodipine helps relax and widen blood vessels, improving blood flow and reducing the heart's workload. This mechanism of action makes it an effective treatment for preventing strokes, heart attacks, and other cardiovascular issues associated with hypertension. Available in various dosages, amlodipine is often prescribed as a once-daily oral tablet and can be used alone or in combination with other antihypertensive agents.

The use of amlodipine has expanded significantly since its introduction, with numerous studies validating its efficacy and safety. It is now one of the most commonly prescribed medications for managing hypertension globally. The drug's popularity is partly due to its relatively mild side effect profile compared to other antihypertensives, making it suitable for long-term use. Moreover, the versatility of amlodipine, both as a monotherapy and in combination with other medications like ACE inhibitors or diuretics, has enhanced its utility in clinical practice. The development of generic versions of amlodipine has also made it more accessible and affordable, contributing to its widespread adoption. In addition to treating hypertension and angina, ongoing research is exploring potential new indications for amlodipine, such as its role in managing coronary artery disease and other cardiovascular conditions.

The growth in the amlodipine market is driven by several factors. Firstly, the increasing prevalence of hypertension and cardiovascular diseases worldwide has significantly boosted the demand for effective antihypertensive medications. Secondly, the aging global population, which is more prone to hypertension and related disorders, has further escalated the need for treatments like amlodipine. Additionally, the continuous advancement in pharmaceutical research has led to the development of improved formulations and combination therapies that enhance patient compliance and therapeutic outcomes. The expansion of healthcare infrastructure in emerging markets has also improved access to hypertension treatments, thereby driving market growth. Furthermore, strategic marketing efforts and educational initiatives by pharmaceutical companies have raised awareness about hypertension management, encouraging more patients to seek treatment. Finally, favorable regulatory environments and the increasing availability of generic versions have made amlodipine more accessible, contributing to its sustained market growth.

Select Competitors (Total 36 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â